Clinical trials: Peptic Ulcer Disease
Stomach Ulcer, Duodenal Ulcer
A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
The purpose of this study is to understand the following safety related particulars associated with the use of Pariet Tablet 5 milligram (mg) to prevent gastric and duodenal ulcer from low dose aspirin administration of 100 mg or…
- Trial name
- NCT05208268
- Testing
- Pariet
- Where
- 29 sites in South Korea
- Volunteers
- 676 people
- Sponsor
- Eisai Korea Inc.
Peptic Ulcer Hemorrhage
Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers
Patients with bleeding ulcers identified by endoscopy will be randomly assigned to receive an acid-blocking drug (called a proton pump inhibitor [PPI]) either by mouth every 3 hours for 24 hours or intravenously (IV) by constant…
- Trial name
- NCT00573924
- Testing
- Proton pump inhibitor (lansoprazole)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Southern California
Gastric or Duodenal Ulcers
Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs
The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) therapy for up to 12 months in the routine clinical setting in patients receiving oral non-steroidal…
- Trial name
- NCT02099708
- Testing
- Lansoprazole
- Volunteers
- 3,502 people
- Sponsor
- Takeda
Peptic Ulcer
Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers
Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.
- Trial name
- NCT02551744
- Testing
- histamine-2 receptor antagonist group, proton pump inhibitor group
- Where
- Taiwan
- Volunteers
- 101 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Ulcer, Gastric, Bile Reflux
Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index
MGB is considered to be the best alternative to Roux-en-Y gastric bypass (RYGB) due to the shorter operation time and fewer possible complications.
- Trial name
- NCT04845438
- Testing
- fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
- Where
- Russia
- Volunteers
- 122 people
- Sponsor
- Private Healthcare Institution Clinical Hospital RGD-Medicine
Bleeding Peptic Ulcer
High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic…
- Trial name
- NCT01757275
- Testing
- Esomeprazole Na, Cimetidine, Esomeprazole Mg
- Where
- 12 sites in China
- Volunteers
- 239 people
- Sponsor
- AstraZeneca
Gastritis, Peptic Ulcer
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
This study aims at evaluating efficacy and safety of berberine-containing quadruple therapy(berberine, esomeprazole, clarithromycin and amoxicillin) versus bismuth-containing quadruple therapy (bismuth,esomeprazole,clarithromycin…
- Conditions
- Gastritis, Peptic Ulcer, Dyspepsia
- Trial name
- NCT02296021
- Testing
- Berberine, Bismuth, esomeprazole
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Duodenal Ulcer, Helicobacter Pylori Infection
Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection
The aims of this study are (1) to evaluate the prevalence rate of PM of CYP2C19 in our country; (2) to evaluate the efficacy of dual therapy with different dose of omeprazole and amoxicillin; (3) to judge the relationship of…
- Trial name
- NCT00854451
- Testing
- omeprazole plus amoxicillin
- Where
- Taiwan
- Volunteers
- 128 people
- Sponsor
- National Taiwan University Hospital
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer.
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma
- Trial name
- NCT01204476
- Testing
- Cixutumumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy
The choice of surgical strategy for patients with proximal gastric cancer is controversial mainly because proximal gastrectomy is infamous for high rates of reflux symptoms and anastomotic stricture.
- Trial name
- PRAPT (NCT01433861)
- Testing
- Laparoscopy-assisted gastrectomy
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Seoul National University Bundang Hospital
Peptic Ulcer
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
- Trial name
- NCT06439563
- Testing
- JP-1366 10 mg, Lanston Capsule 15 mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Onconic Therapeutics Inc.
Helicobacter Pylori Gastritis, Helicobacter Eradication
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia
The goal of this clinical trial is to learn if a modified bismuth-containing therapy for the treatment of helicobacter pylori infection works to treat chronic helicobacter pylori related gastritis in adults treated either for…
- Trial name
- MBISQ4HP (NCT07146594)
- Testing
- Modified bismuth-containing eradication treatment
- Volunteers
- 150 people
- Sponsor
- Athens Medical Center
Stomach Ulcer
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?
Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH).
- Trial name
- NCT01167101
- Testing
- Rebamipide, pantoprazole
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Kangdong Sacred Heart Hospital
Prevention
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from…
- Trial name
- NCT01069939
- Testing
- Esomeprazole
- Where
- 46 sites in Japan, South Korea and 1 more
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers
Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.
- Conditions
- Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers
- Trial name
- NCT06098742
- Testing
- Antareit
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Functional Dyspepsia, Gastro Esophageal Reflux
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
The purpose of this prospective cohort study is to compare upper GI symptoms and endoscopy findings in Canada with Japan and Iran, and correlate this with the upper GI microbiome.
- Conditions
- Functional Dyspepsia, Gastro Esophageal Reflux, Peptic Ulcer, Normal Control
- Trial name
- NCT03868267
- Where
- 3 sites in Canada, Iran and 1 more
- Volunteers
- 1,500 people
- Sponsor
- Hamilton Health Sciences Corporation
Peptic Ulcer Hemorrhage
Supplementary Angiographic Embolization for Peptic Ulcer Bleeding
Peptic ulcer bleeding is a common disorder. Despite optimal endoscopic and medical treatment, there is a high risk of rebleeding and high mortality.
- Trial name
- NCT01125852
- Testing
- Angiographic embolization, Therapeutic endoscopy
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Odense University Hospital
Peptic Ulcer Hemorrhage
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
The purpose of this study is to evaluate the efficacy and safety of intravenous pantoprazole in the prevention of rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.
- Trial name
- NCT00040495
- Testing
- Pantoprazole
- Volunteers
- 149 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Peptic Ulcer Hemorrhage
Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding
A large dose of PPI is effective in preventing peptic ulcer rebleeding. The investigators hypothesize that 40 mg/q6h pantoloc is equivalent to 8mg/h pantoloc in preventing rebleeding.
- Trial name
- PPI (NCT00731601)
- Testing
- pantoprazole
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Lotung Poh-Ai Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD